We read with interest the excellent article by Ting and colleagues1 about risk factors of vitamin B12 deficiency in patients receiving metformin. We would like to offer some findings from our own experience. To date, more than 30 patients with metformin-associated vitamin B12 deficiency have been registered in a cohort study of cobalamin deficiency in the University Hospital of Strasbourg, Strasbourg, France (partial data were previously published2). An analysis of these patients (median age, 66 years) proves some of the comments by Ting et al.1 First, the clinical severity of metformin-associated vitamin B12 deficiency is moderate, with 90% of minor hematological abnormalities (median hemoglobin levels and mean erythrocyte cell volume, 11.5 g/dL and 95.4 fL, respectively) and 30% of mild peripheral sensitive neuropathy. However, there were 2 cases (5.7%) of symptomatic anemia and pancytopenia (requiring transfusions). The mean ± SD serum vitamin B12 and total homocysteine levels were 156 ± 31 pg/mL (range, 87-200 pg/mL) (115.1 ± 22.9 pmol/L [range, 64-148 pmol/L) and 2.0 ± 0.8 mg/L (range, 2-3 mg/L) (14.8 ± 5.7 μmol/L [range, 13-22 μmol/L]). Second, an analysis of our cases suggests that the principal mechanism of vitamin B12 deficiency in patients receiving metformin is undoubtedly food-cobalamin malabsorption. In fact, of 34 patients' responses to the diagnostic criteria we had previously published,3 1 patient had a malabsorption with chronic diarrhea.2 In our opinion, this mechanism of food-cobalamin malabsorption may explain the constant efficacy of oral crystalline cyanocobalamin therapy that we have observed as a benefit of calcium supplementation. To our knowledge, discontinuation of metformin therapy remains controversial, but our results suggest that it may be unnecessary.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.